LAUSR

Volanesorsen: First Global Approval

Sign Up to like & get
recommendations!
0 Published in 2019 at "Drugs"

DOI: 10.1007/s40265-019-01168-z

Abstract: Volanesorsen (Waylivra®), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL).… read more here.

Keywords: volanesorsen first; global approval; volanesorsen; first global ... See more keywords